Brief: Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder
19/05/2025 12:43
May 19 (Reuters) - Altimmune Inc ALT.O: ALTIMMUNE ANNOUNCES INITIATION OF RECLAIM PHASE 2 TRIAL EVALUATING THE EFFICACY AND SAFETY OF PEMVIDUTIDE IN ALCOHOL USE DISORDER (AUD) ALTIMMUNE INC - IMPACT PHASE 2B TRIAL TOPLINE DATA EXPECTED IN Q2 2025 ALTIMMUNE INC - PHASE 2 TRIAL IN ALD TO INITIATE ENROLLMENT IN Q3 2025 Source text: ID:nGNXYx2DK Further company coverage: ALT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Altimmune
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat
U.S. RESEARCH ROUNDUP-Costco Wholesale, HCA Healthcare, Micron Technology
Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial (updated)